CD4 and prostate cancer: Following this observation, we did a meta-analysis of mDCs and HLA-DR+CD4+ pDCs in PBMCs from prostate cancer (PC) and ovarian cancer (OvCa) patients and frequencies were compared to those identified in healthy donors (HD) (Supplementary Figure 2).